Protein / target
Gastric inhibitory polypeptide receptor
Protein at a glance
Biological role
Gastric inhibitory peptide receptor
Strongest disease association
Obesity disorder
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
This is a receptor for GIP.
View complete UniProt function annotationHide complete annotation
This is a receptor for GIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase
Subcellular location
Domains and Gene Ontology detail (22)Hide
Gene Ontology
- Cmembrane
- Cplasma membrane
- FG protein-coupled peptide receptor activity
- Fgastric inhibitory peptide receptor activity
- Fglucagon family peptide binding
- Fpeptide hormone binding
- Ftransmembrane signaling receptor activity
- Pactivation of adenylate cyclase activity
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
- Padenylate cyclase-modulating G protein-coupled receptor signaling pathway
- Pcell surface receptor signaling pathway
- Pdesensitization of G protein-coupled receptor signaling pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Lipid & lipoprotein metabolism
- ·response to fatty acid
G protein-coupled signalling
- ·G protein-coupled peptide receptor activity
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
- ·adenylate cyclase-modulating G protein-coupled receptor signaling pathway
- ·desensitization of G protein-coupled receptor signaling pathway
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Gastric inhibitory polypeptide receptor agonist
Indicated for Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity, Overweight
Gastric inhibitory polypeptide receptor agonist
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene GIPR
Gene-level evidence surfaced through the gene GIPRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
2 compounds recorded · 1 approved · 1 in clinical development
View all recorded compounds (2)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (15)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- New publicationGLP-1 and the cardiovascular system.
- New publicationGlucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
- New publicationThe Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
- New publicationNeurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.
- New publicationReal-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
- New publicationClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
- New publicationGLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.
- New publicationWhy does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
- New publicationClinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.
- New publicationTirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
- Regulatory approval
Approval: Mounjaro (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.